Global Dextran 40 Glucose Injection Market Size To Worth USD 2.06 Billion By 2033 | CAGR Of 6.00%
Category: HealthcareGlobal Dextran 40 Glucose Injection Market Size To Worth USD 2.06 Billion By 2033
According to a research report published by Spherical Insights & Consulting, The Global Dextran 40 Glucose Injection Market Size is expected to Grow from USD 1.15 Billion in 2023 to USD 2.06 Billion by 2033, at a CAGR of 6.00% during the forecast period 2023-2033.
Get more details on this report -
Browse key industry insights spread across 212 pages with 100 Market data tables and figures & charts from the report on the “Global Dextran 40 Glucose Injection Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Intramuscular Injection and Intravenous Injection), By Application (Thrombosis, Hypovolemia, and Others), By End-User (Clinics, Hospitals, Ambulatory Surgical Centers, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033.” Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/dextran-40-glucose-injection-market
The dextran 40 glucose injection market is a pharmaceutical industry that uses intravenous solutions containing dextran 40, a bacterial fermentation polysaccharide, combined with glucose to treat hypovolemia and enhance plasma volume in critical care situations. Dextran 40 is a sterile, nonpyrogenic, and odourless white powder that dissolves gradually in water. It is used in medical treatment procedures, particularly in hypovolemic shock and microcirculation, and in surgical operations to prevent blood clotting and improve blood flow. The market is expanding due to the increasing prevalence of thromboembolic disorders, such as venous thromboembolism (VTE), chronic illnesses, and the increasing elderly demographic. Technological advancements, improved healthcare infrastructure, and increased healthcare spending are contributing to the market growth. The anticoagulant activity of the dextran 40 injection is essential for preventing and managing thrombosis. However, the high cost of the dextran 40 glucose injection may impede market growth.
The intravenous injection segment held the largest share in 2023 and is predicted to grow at a significant CAGR during the predicted period.
Based on the product type, the global dextran 40 glucose injection market is categorized as intramuscular injection and intravenous injection. Among these, the intravenous injection segment held the largest share in 2023 and is predicted to grow at a significant CAGR during the predicted period. This is attributed to its rapid action, avoidance of first-pass metabolism, enhanced bioavailability, accurate dosing, flexibility, direct systemic circulation, decreased injection site irritation, long-term management, and ability to administer complex pharmaceutical active ingredients.
The hypovolemia segment accounted for the highest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the application, the global dextran 40 glucose injection market is categorized as thrombosis, hypovolemia, and others. Among these, the hypovolemia segment accounted for the highest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segment's growth is attributed to factors such as reduced blood volume, increased hypovolemia prevalence, effective treatment, advancements in medical technology, geriatric population growth, and increasing trauma cases.
The hospitals segment held the highest share in 2023 and is predicted to grow at a significant CAGR throughout the projected timeframe.
Based on the end-user, the global dextran 40 glucose injection market is categorized in to clinics, hospitals, ambulatory surgical centers, and others. Among these, the hospitals segment held the highest share in 2023 and is predicted to grow at a significant CAGR throughout the projected timeframe. The segment's growth is attributed to the increasing volume of surgical procedures, increased in-patient services, emergency procedures, improved healthcare infrastructure, chronic conditions, and advancements in medical devices.
North America is expected to hold the greatest share of the global dextran 40 glucose injection market over the forecast period.
Get more details on this report -
North America is expected to hold the greatest share of the global dextran 40 glucose injection market over the forecast period. The market for dextran 40 glucose injection in North America is driven by advanced healthcare infrastructure, high costs, and growing provider awareness. The market is expanding due to major pharmaceutical companies and continuous research and development. The aging population and increasing incidence of diseases like thrombosis and hypovolemia are expected to drive demand. dextran 40 glucose injection's effectiveness and shelf life have increased due to better formulations. The need for efficient plasma volume expanders is also increasing due to the aging population and chronic illnesses.
Asia Pacific is predicted to grow at the fastest CAGR throughout the estimated period. The Asia-Pacific region is experiencing significant growth due to investments in healthcare facilities, medical tourism, and improved infrastructure. Emerging markets like China, India, and Japan have a large population and better access to medical care. Government initiatives to enhance healthcare quality and accessibility are expected to drive market expansion. The aging population drives demand for efficient therapies, and economic development in countries like China and India allows for more affordable treatments and improved facilities.
Major key players in the global dextran 40 glucose injection market are Grifols, S.A., Amgen Inc., Sanofi S.A., B. Braun Melsungen AG, Baxter International Inc., Hospira, Inc., Boehringer Ingelheim GmbH, Novartis AG, Roche Holding AG, Merck & Co., Inc., Abbott Laboratories, Otsuka Pharmaceutical Co., Ltd., and others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Recent Development
- In September 2024, The U.S. Food and Drug Administration (FDA) approved Pfizer's emergency application to extend the Use Date for one lot of 10% LMD in 0.9% Sodium Chloride Injection (Dextran 40 in Sodium Chloride Injection) USP, NDC 0409-7419-03, and one lot of 10% LMD in 5% Dextrose Injection (Dextran 40 in Dextrose Injection) USP, NDC 0409-7418-03 to address a shortage of these vital products.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global dextran 40 glucose injection market based on the below-mentioned segments:
Global Dextran 40 Glucose Injection Market, By Product Type
- Intramuscular Injection
- Intravenous Injection
Global Dextran 40 Glucose Injection Market, By Application
- Thrombosis
- Hypovolemia
- Others
Global Dextran 40 Glucose Injection Market, By End-User
- Clinics
- Hospitals
- Ambulatory Surgical Centers
- Others
Global Dextran 40 Glucose Injection Market, By Regional
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?